Pre-Existing Autoimmune Disease and Mortality in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy

Article Dermatology

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy

Kimberly Tang et al.

Summary: This study investigated the association between the occurrence of immune-related skin adverse events and patient survival in individuals treated with immune checkpoint inhibitors. The results showed a strong association between the occurrence of these skin adverse events and response to treatment and patient survival.

JAMA DERMATOLOGY (2022)

添加到收藏夹

Review Oncology

Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis

R. Park et al.

Summary: A pan-cancer meta-analysis showed a correlation between immune-related adverse events (irAEs) and clinical outcomes, indicating irAEs could serve as useful clinical biomarkers for predicting overall response rate, overall survival, and progression-free survival across different cancer types.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Julianne D. Twomey et al.

Summary: ICIs, targeting PD-1 or PD-L1, have become a new standard-of-care for many cancer indications, approved by the FDA. This review focuses on their clinical indications, companion diagnostics, and strategies for identifying predictive biomarkers for guiding their clinical use.

AAPS JOURNAL (2021)

添加到收藏夹

Article Oncology

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

Xue Bai et al.

Summary: A multicenter retrospective analysis found that early high-dose GCC use was associated with poorer survival outcomes in melanoma patients after anti-PD-1 monotherapy, highlighting the need for cautious use of GCC. These findings were validated in a combined validation cohort, confirming the association between high-dose GCC use and worse prognosis.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Medicine, General & Internal